immncorp1801
Primary Menu
About Us
Technology
Pipeline
Patients
News hub
News
Events
Careers
Menu
About Us
Technology
Pipeline
Patients
News hub
Careers
News
Archive / 2017
11 December 2017
Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma
13 November 2017
Immunocore Presents Single Agent IMCgp100 data in Metastatic Uveal Melanoma Showing Durability, Doubling in One-Year Overall Survival Rate
31 October 2017
Immunocore to Present New Overall Survival Data in Metastatic Uveal Melanoma at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
4 October 2017
Immunocore Appoints Andrew Hotchkiss as Chief Commercial Officer
18 September 2017
Immunocore and the Bill & Melinda Gates Foundation Collaborate to Develop Immunotherapies for Infectious Diseases
7 July 2017
Immunocore and MEPC announce significant laboratory expansion at Milton Park in Oxfordshire, UK
3 July 2017
Immunocore Announces Third Oncology Target Selected in Discovery Collaboration with GlaxoSmithKline
5 June 2017
Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting
1 June 2017
Immunocore Highlights IMCgp100 clinical data in Uveal Melanoma at ASCO 2017 Annual Meeting
12 May 2017
Abbas Hussain Joins the Board of Immunocore as Non-Executive Director
← Previous
1
(current)
2
Next →
Sign-up to receive news email alerts
Email address
Send
Please enter a valid email address
Thankyou. You have successfully subscribed to news updates.
News archive
Show all
2019 (2)
2018 (10)
2017 (13)
2016 (11)
2015 (20)
2014 (6)
2013 (11)
2012 (3)
2011 (1)
2010 (4)
2009 (1)
2008 (1)